Jade Biosciences, Inc. · NASDAQ:JBIO
Jade Biosciences — JADE201 Conference Call and Webcast (October 2025)
15 slides from Jade Biosciences's conference presentation, Oct 7, 2025
Slide 1: JADE201 Conference Call and Webcast
JADE201 Conference Call and Webcast October 7, 2025 NASDAQ: JBIO
Slide 2: Disclaimers
Disclaimers Forward Looking Statements Certain statements in this presentation, other than purely historical information, may constitute "forward-looking statements" within the meaning of the federal securities laws, including for purposes of the "safe harbor" provisions under the Private Securities
Slide 3: Jade Biosciences is advancing potentially best-in-class therapies for autoimmune diseases
Jade Biosciences is advancing potentially best-in-class therapies for autoimmune diseases Additional financing totaling $135 million in gross proceeds supports cash runway into H1 2028 MOA Program Candidate Discovery IND-enabling Phase 1 Expected Milestones Potential Indications • Interim Data: anti
Slide 4: JADE201: afucosylated anti-BAFF-R mAb
JADE201: afucosylated anti-BAFF-R mAb 4
Slide 5: JADE201, a potentially best-in-class afucosylated anti-BAFF-R mAb with dual MOA B cell depletion
JADE201, a potentially best-in-class afucosylated anti-BAFF-R mAb with dual MOA B cell depletion to treat autoimmune diseases • B cell depletion has proven effective in autoimmune disease, but existing therapies like rituximab and anti-CD19 agents face limits: Incomplete B cell Residual B cells in R
Slide 6: JADE201's dual MOA expected to deliver deeper, more durable B cell depletion
JADE201's dual MOA expected to deliver deeper, more durable B cell depletion Direct Cytotoxicity via Enhanced Effector Function B Cell Inhibition and Depletion by BAFF Starvation • Validated mechanism that induces rapid B cell • Mechanism works in context of low receptor depletion expression • Enhan
Slide 7: Potentially best-in-class properties of JADE201
Potentially best-in-class properties of JADE201 Binds BAFF-R broadly expressed on B cells • Enhanced ADCC activity on B cells similar to ianalumab • Blocks BAFF activity similar to ianalumab HLE via Fc LS mutation • Predicted to match, with potential for improved clinical activity due to increased e
Slide 8: JADE201 retains high BAFF-R binding affinity and functional activity in preclinical studies
JADE201 retains high BAFF-R binding affinity and functional activity in preclinical studies BAFF-R Binding (HEK Cells) BAFF-R Blockade (Competition ELISA) ADCC Activity – Primary human CD19+ B Cells Additional Attributes Similar Between Clones 3000 • Affinity to human/cyno BAFF-R by SPR Live B cells
Slide 9: JADE201 demonstrates deep B cell depletion in NHPs
JADE201 demonstrates deep B cell depletion in NHPs JADE201 PK PK BAFF-Receptor Occupancy Receptor Occupancy BBCell Cell Depletion Depletion 1000000 120 140 JADE201 Concentration (ng/ml) 0.001mg/kg 0.001mg/kg Mean (±SEM) B Cell Density 100000 100 120 0.01mg/kg 0.01mg/kg BAFF RO on B Cells (count/ul)
Slide 10: JADE201 demonstrates a differentiated NHP PK profile from ianalumab
JADE201 demonstrates a differentiated NHP PK profile from ianalumab HLE has potential to provide sustained BAFF receptor >2X HLE demonstrated in NHPs occupancy and improved clinical response • Ianalumab has an observed human T1/2 ~ 10 days JADE201 NHP • JADE201 with HLE has the potential to provide
Slide 11: JADE201 first-in-human trial in rheumatoid arthritis patients on track to begin in H1 2026
JADE201 first-in-human trial in rheumatoid arthritis patients on track to begin in H1 2026 Phase 1 Study Design Endpoints Randomized, double-blind, placebo-controlled SAD study Primary SC administration in adults (n=36) with rheumatoid arthritis. ● Safety and tolerability SC Dose 6: N = 5:1 Secondar
Slide 12: JADE201 profile expected to enable broad opportunity in multiple indications
JADE201 profile expected to enable broad opportunity in multiple indications, including potential best-in-class and first-in-class Rheumatology Neurology Gastroenterology • ANCA – Associated Vasculitis • Multiple Sclerosis • Autoimmune Hepatitis • Autoimmune Myositis • Myasthenia Gravis • Primary Bi
Slide 13: Jade Biosciences is advancing potentially best-in-class therapies for autoimmune diseases
Jade Biosciences is advancing potentially best-in-class therapies for autoimmune diseases Additional financing totaling $135 million in gross proceeds supports cash runway into H1 2028 MOA Program Candidate Discovery IND-enabling Phase 1 Expected Milestones Potential Indications • Interim Data: anti
Slide 14: Jade Biosciences Q&A
Jade Biosciences Q&A Tom Frohlich Andrew King, BVMS, Ph.D. Brad Dahms Chief Executive Officer Chief Scientific Officer & Head of R&D Chief Financial Officer 14
Slide 15: Thank you
Thank you www.JadeBiosciences.com | info@jadebiosciences.com NASDAQ: JBIO
Jade Biosciences — JADE201 Conference Call and Webcast (October 2025) on 6ix